All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-01-30T00:00:00.000Z

Intra-arterial steroid administration in patients with steroid-refractory acute gastrointestinal graft-versus-host disease

Jan 30, 2019
Share:

Limited number of studies have shown that intra-arterial steroid administration (IASA) into the superior (SMA) and/or inferior mesenteric arteries (IMA) may be a feasible second-line therapy option for patients with steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGvHD). Viktor Berczi from the Department of Radiology, Semmelweis University, Budapest, Hungary, and colleagues retrospectively analyzed the clinical effectiveness of IASA treatment in adult patients with SR GI aGvHD following hematopoietic stem cell transplantation (HSCT). The analysis was published ahead of print in Clinical Radiology.

Patients and methods

  • N = 10 consecutive adult patients
  • Median age: 42 years; range, 19–61 years
  • Patients had ≥ stage II GI aGvHD and were refractory to intravenous methylprednisolone
  • All patients received IASA into the SMA and/or IMA
  • The severity of aGvHD was determined as the volume of diarrhoea (stages 0-IV), and the Glucksberg grading system before and 12±3 SD, 27±4 and 54±6 days after IASA treatment
  • Median follow-up: 65 days (range, 22–370)

Key findings

  • GI responses after IASA:
    • Patients responding at 12 days: 6/10
    • Patients responding at 27 days: 8/10
    • Patients responding at 54 days: 6/10
  • Complete GI response after IASA:
    • At 12 days: 1/10 patients
    • At 27 days: 4/10 patients
    • At 54 days: 4/10 patients
  • Four patients who reached complete resolution of GI aGvHD at day 12 or 27 showed a sustained symptom-free state
  • One patient showed only a temporary response
  • Five patients died between days 22 and 67

The authors concluded that IASA “is a safe and effective method to treat SR GI aGvHD in patients who have failed to respond to first-line treatment with intravenous steroids.” Further studies are required to assess the efficacy of IASA and to identify possible prognostic factors associated with a successful outcome in this patient population.

  1. Bérczi V. et al. Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Clin Rad. 2019 Jan 25. DOI: 1016/j.crad.2018.11.013. [Epub ahead of print].


Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox